After 12 weeks , ezetimibe significantly reduced LDL-C by 27 % after adjustment for placebo ( P < .001 ) and produced significant reductions in total cholesterol ( 21 % ) , nonhigh-density lipoprotein cholesterol ( 26 % ) , and apolipoprotein B ( 20 % ) ( P < .001 for all ) .